NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma – a case report and review of the literature
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background: The prognosis and treatment of metastatic osteosarcoma have not changed in the last decades and the responses to chemotherapy in this setting are disappointing. In the past years, immunotherapy has found its place in the treatment of different tumor types. Its role in the treatment of sarcomas, and in particular osteosarcoma, is less clear. Next-generation sequencing (NGS) can help identify patients who could benefit from immunotherapy.Methods: Single case study and review of the literatureCase summary and intervention: We discuss a case of a 26-year-old man with a metastatic osteosarcoma not responsive to several lines of standard chemotherapy. NGS-analysis of resected tumor tissue revealed amplification of PD-L1 and PD-L2, which is associated in literature with response to anti-PD-1/PD-L1 blockade in other tumor types and in osteosarcoma mouse models. Treatment of our patient with the combination of an anti-PD-1 antibody (Nivolumab) and an anti-CTLA4 antibody (Ipilimumab) showed a stabilization of life-threatening retrocardiac tumoral masses that had previous significantly progressed despite radiotherapy, while one bone lesion in the right os ilium was growing and needed treatment with concomitant radiotherapy.Conclusion: To our knowledge, this is the first case report of a metastasized osteosarcoma patient with no further standard treatment options being treated with dual checkpoint inhibition. A complete stabilization of life-threatening retrocardiac lesions could be achieved and with the addition of radiotherapy to a growing bone lesion, the patient is still doing well. NGS-analysis can help identify druggable targets in patients with rare tumors with limited treatment options.Abbreviations: PD-L1: Programmed death-ligand 1; anti-PD-L1: anti-programmed death-ligand 1; PD-1: programmed cell death protein 1; anti-PD-1: anti-programmed cell death protein 1; anti-CTLA4: anti-cytotoxic T-lymphocyte-associated protein 4; AUC: area under the curve; NGS: next-generation sequencing; Gy: Gray; CT scan: computed tomography scan; RCC: renal cell carcinoma; IHC: immunohistochemistry; TMB: tumor mutational burden; NSCLC: Non-small cell lung cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A case report demonstrated that the combination of an anti-PD-1 antibody (nivolumab) and an anti-CTLA-4 antibody (ipilimumab) inhibited the progression of metastatic tumor for a young man with a metastatic osteosarcoma not responsive to several lines of standard chemotherapy.”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [153]
In the citing paper
“they detected the amplification of PD-L1 and PD-L2 in resected tumor tissue through next-generation sequencing”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [153]
Citations
Cites
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 6×
“hood of response are microsatellite instability (MSI) and high tumormutational burden (TMB) [13,17].”
BackgroundInfluentialNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 3×
“untreated intermediate- and poor-risk advanced RCC [8].”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Inmelanoma, dual checkpoint inhibition is now part of the standard of care as it showed higher objective response rates compared to PD-1 blockade alone in a phase III trial [7].”
ResultPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 1×
“explains why PD-L1 testing alone is insufficient for patient selection in most malignancies [13,14].”
BackgroundCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · cited 9×
“PD-L1 amplification has therefore been suggested as predictive biomarker [4,13].”
BackgroundInfluentialOsteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“However, in the abovementioned phase 2 trial in sarcoma patients, only 4% of the total population had a positive PD-L1 expression (defined as a positive staining of >1%) and none of those had an osteosarcoma [6].”
BackgroundTranslational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · cited 1×
“metastatic setting, including the use of checkpoint inhibitors [9].”
BackgroundRecurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Geller, D. S., & Gorlick, R. G. (2010) · PubMed · Cited by 475
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Goodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H.-Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 247
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · cited 2×
“Eventually, tumors in thesemousemodels became resistant to anti-PD-1 by upregulation of inhibitory receptors on tumor-infiltrating lymphocytes, including CTLA-4 [5].”
BackgroundEnhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197 · cited 1×
“In K7M2 mouse models of metastatic osteosarcoma, blockade of PD-1/PD-L1 resulted in decreased tumor burden and increased survival [10].”
BackgroundProgrammed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G. P., Chebib, I., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 193
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Mansfield, A. S., Murphy, S. J., Peikert, T., Yi, E. S., Vasmatzis, G., Wigle, D. A., & Aubry, M. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2246 · Cited by 134
Immune Checkpoint Inhibitors in NSCLC
Johnson, D. B., Rioth, M. J., & Horn, L. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0305-5 · Cited by 84
Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience
Cote, G. M., He, J., & Choy, E. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0290 · Cited by 76
Groisberg, R., Roszik, J., Conley, A. P., PATEL, S. R., & Subbiah, V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0641-2 · Cited by 39
Microsatellite instability in sarcomas
Martin, S. S., Hurt, W. G., Hedges, L. K., Butler, M. G., & Schwartz, H. S. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303500 · Cited by 25
Emerging Role for Precision Therapy Through Next-Generation Sequencing for Sarcomas
Wilky, B. A., & Villalobos, V. M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00261 · Cited by 3
Research works printed but not linked: 1
- Geller DS, 2010, Clin Adv Hematol Oncol, 8, 705
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Thus it can be seen, it is important that identifying biomarkers to select patients with high response rates to immunotherapy [153].”
BackgroundPanez-Toro, I., Muñoz-García, J., Vargas-Franco, J. W., Renodon‐Cornière, A., Heymann, M., Lézot, F., & Heymann, D. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00803-9 · Cited by 144
Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential
Yang, W., Tang, F., Tu, C., Hornicek, F. J., Duan, Z., & Min, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215887 · Cited by 114
Novel Immunotherapies for Osteosarcoma
Lu, Y., Zhang, J., Chen, Y., Kang, Y., Liao, Z., He, Y., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830546 · Cited by 66
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 51
Metadata
- Authors
- Nuytemans, L., Sys, G., Creytens, D., & Lapeire, L.
- Affiliations
- Ghent University Hospital (BE)
- Corresponding author
- Nuytemans, Laure
- Venue
- Acta Clinica Belgica
- Publisher
- Informa UK Limited
- Published
- 2019-10-21
- Volume
- 76
- Issue
- 2
- Pages
- 162-167
- ISSN
- 1784-3286 (ISSN-L)
- 2295-3337
- OpenAlex
- W2982082744
- Cited by
- 16
- References
- 24
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- biblio.ugent.be
- Licence
- other-oa
- Locations
- Acta Clinica Belgica (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (publishedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- metastatic osteosarcoma, PD-L2, anti-PD-1, nivolumab, anti-CTLA-4 antibody, ipilimumab, immunotherapy, next-generation sequencing, tumor mutational burden, radiotherapy
- MeSH terms
- Adult, Animals, Carcinoma, Non-Small-Cell Lung, Humans, Kidney Neoplasms, Lung Neoplasms, Male, Osteosarcoma, Mice, High-Throughput Nucleotide Sequencing, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.